Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
References Novartis ianalumab first drug to reduce disease activity and patient burden in Sjgrens disease Phase III trials, 29 October 2025, Novartis, Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients with Active Sjogrens Syndrome (NEPTUNUS-1), ClinicalTrials.gov ID NCT05350072, Abstract Number: LB24: Ianalumab demonstrates significant reduction in disease activity in patients with Sjgrens disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2), American College of Rheumatology, A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome
Mech Ageing Dev (2020) 192:111385
Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial
The duration of GLP-1 medication use is ideally indefinite, though some people maintain with lower doses or explore microdosing protocols for ongoing maintenance
Iron British Dietetic Association
US$ 25.87
US$ 29.42
US$ 24.84
US$ 21.33
US$ 25.14
US$ 20.75
US$ 21.42
US$ 26.83
US$ 21.10
US$ 24.80
US$ 21.97
US$ 28.84
